Should Myeloma Residual Disease Become a Standard Assay for Large Cooperative Groups and Myeloma Referral Centers?
Episode Description
Minimal residual disease predicts outcomes in myeloma.
We use cookies to run this site. Analytics cookies help us understand how you use it and are off until you say yes. You can change your mind at any time from the privacy preferences icon at the bottom right.We use cookies to run this site and to understand how it's used. You can opt out at any time from the privacy preferences icon at the bottom right. Cookie policy